EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy

K Sandeep, Kavitha C Venugopal, Akshatha P Javagal, Pavana Acharya, S R Sreelekshmi, N Narendra, P K Nayana

Indian Journal of Ophthalmology · 2023-10 · 71 (10) · 3381-3385

DOI: 10.4103/ijo.ijo_169_23 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 29.09.2023. Verfasst von K Sandeep und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan, Karnataka, India. Hauptthemen laut MEDLINE: Central Serous Chorioretinopathy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare the efficacy of oral propranolol, oral rifampicin, and intravitreal anti-VEGF therapies on resolution-time and visual outcome in patients with central serous chorioretinopathy (CSCR).

Methods

A total of 30 patients with CSCR were randomized into three groups of 10 patients. Group A was given oral propranolol, Group B was given oral rifampicin 4 weeks each, and Group C was given 0.05 ml intravitreal injection of anti-VEGF. Comparisons of mean BCVA, contrast sensitivity, and central macular thickness (CMT) performed between baseline and follow-up at 4 weeks, 6 weeks, and 3 months.

Results

Statistically significant improvement in BCVA and contrast sensitivity was noted among all three groups. Complete resolution of SRF as indicated by CMT was seen at the end of 4 weeks in Group C, whereas there was a steady decline in CMT until 3 months in Groups A and B.

Conclusion

Intravitreal anti-VEGF therapy shows a significantly faster SRF resolution. However, oral propranolol and oral rifampicin could prove as a useful, cost-effective treatment of CSCR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Serous ChorioretinopathyHumansPropranololRifampinTreatment OutcomeTomography, Optical CoherenceIntravitreal Injections

Stichwörter der Autor:innen

Anti-VEGFcentral serous chorioretinopathypropranololrifampicin

Substanzen

PropranololRifampin

Autor:innen und Institutionen

  • Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan, Karnataka, India.

Zitieren

APA

Sandeep, K., Venugopal, K. C., Javagal, A. P., Acharya, P., Sreelekshmi, S. R., Narendra, N., & Nayana, P. K. (2023). Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy. Indian Journal of Ophthalmology, 71(10), 3381-3385. https://doi.org/10.4103/ijo.ijo_169_23

Vancouver

Sandeep K, Venugopal KC, Javagal AP, Acharya P, Sreelekshmi SR, Narendra N, et al. Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy. Indian Journal of Ophthalmology. 2023;71(10):3381-3385. doi:10.4103/ijo.ijo_169_23

BibTeX
@article{Sandeep2023,
  author = {Sandeep, K and Venugopal, Kavitha C and Javagal, Akshatha P and Acharya, Pavana and Sreelekshmi, S R and Narendra, N and Nayana, P K},
  title = {Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy},
  journal = {Indian Journal of Ophthalmology},
  year = {2023},
  volume = {71},
  number = {10},
  pages = {3381--3385},
  doi = {10.4103/ijo.ijo_169_23}
}
Kostenlos starten →